Does Rallies show 13F holders for CNSP?

Yes. Rallies tracks hedge fund and 13F ownership data for CNSP, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CNSP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CNSP. It does not provide personalized investment advice.

CNSP (CNS Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

CNS Pharmaceuticals, Inc. Common Stock (CNSP) is a publicly traded Healthcare sector company. As of May 21, 2026, CNSP trades at $4.98 with a market cap of $3.82M and a P/E ratio of -0.14. CNSP moved +10.88% today. Year to date, CNSP is -3.43%; over the trailing twelve months it is -67.05%. Its 52-week range spans $1.90 to $221.94. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces CNSP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CNSP stock?

Hedge funds tracked by Rallies that own CNSP include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for CNS Pharmaceuticals, Inc. Common Stock.

CNSP Key Metrics

Key financial metrics for CNSP
Metric	Value
Price	$4.98
Market Cap	$3.82M
P/E Ratio	-0.14
EPS	$-35.75
Dividend Yield	0.00%
52-Week High	$221.94
52-Week Low	$1.90
Volume	243
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-15.85M
Gross Margin	0.00%

Top Hedge Funds Holding CNSP

Citadel Advisors holds 321.87K shares of CNSP, changed +253.58% as of Dec 31, 2024.

Latest CNSP News

CNS Pharmaceuticals Raises $22.5M, Launches Acquisition-Driven Strategy — May 14, 2026
CNS Pharmaceuticals Plans Out-Licensing of Berubicin, TPI 287 to Fund Neurology and Oncology Acquisitions — Mar 11, 2026
CNS Pharmaceuticals Appoints Lynne Kelley as CMO with 20-Year Phase 1-3 Leadership — Mar 2, 2026
CNS Pharmaceuticals Appoints CFO, CTO and CBO with 15–30 Years Experience — Feb 17, 2026

Recent CNSP Insider Trades

Charles Faith L. bought 7.10K (~$34.00K) on May 18, 2026.
Gumulka Jerzy bought 33.33K (~$10.00K) on Feb 1, 2024.
Evans Carl Anthony bought 33.33K (~$10.00K) on Feb 1, 2024.

CNSP Analyst Consensus

1 analysts cover CNSP: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.

Common questions about CNSP

Who owns CNSP stock?: Hedge funds tracked by Rallies that own CNSP include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for CNS Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for CNSP?: Yes. Rallies tracks hedge fund and 13F ownership data for CNSP, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CNSP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CNSP. It does not provide personalized investment advice.